Literature DB >> 17200475

Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis.

Lise E Nigrovic1, Nathan Kuppermann, Charles G Macias, Christopher R Cannavino, Donna M Moro-Sutherland, Robert D Schremmer, Sandra H Schwab, Dewesh Agrawal, Karim M Mansour, Jonathan E Bennett, Yiannis L Katsogridakis, Michael M Mohseni, Blake Bulloch, Dale W Steele, Ron L Kaplan, Martin I Herman, Subhankar Bandyopadhyay, Peter Dayan, Uyen T Truong, Vincent J Wang, Bema K Bonsu, Jennifer L Chapman, John T Kanegaye, Richard Malley.   

Abstract

CONTEXT: Children with cerebrospinal fluid (CSF) pleocytosis are routinely admitted to the hospital and treated with parenteral antibiotics, although few have bacterial meningitis. We previously developed a clinical prediction rule, the Bacterial Meningitis Score, that classifies patients at very low risk of bacterial meningitis if they lack all of the following criteria: positive CSF Gram stain, CSF absolute neutrophil count (ANC) of at least 1000 cells/microL, CSF protein of at least 80 mg/dL, peripheral blood ANC of at least 10,000 cells/microL, and a history of seizure before or at the time of presentation.
OBJECTIVE: To validate the Bacterial Meningitis Score in the era of widespread pneumococcal conjugate vaccination. DESIGN, SETTING, AND PATIENTS: A multicenter, retrospective cohort study conducted in emergency departments of 20 US academic medical centers through the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. All children aged 29 days to 19 years who presented at participating emergency departments between January 1, 2001, and June 30, 2004, with CSF pleocytosis (CSF white blood cells > or =10 cells/microL) and who had not received antibiotic treatment before lumbar puncture. MAIN OUTCOME MEASURE: The sensitivity and negative predictive value of the Bacterial Meningitis Score.
RESULTS: Among 3295 patients with CSF pleocytosis, 121 (3.7%; 95% confidence interval [CI], 3.1%-4.4%) had bacterial meningitis and 3174 (96.3%; 95% CI, 95.5%-96.9%) had aseptic meningitis. Of the 1714 patients categorized as very low risk for bacterial meningitis by the Bacterial Meningitis Score, only 2 had bacterial meningitis (sensitivity, 98.3%; 95% CI, 94.2%-99.8%; negative predictive value, 99.9%; 95% CI, 99.6%-100%), and both were younger than 2 months old. A total of 2518 patients (80%) with aseptic meningitis were hospitalized.
CONCLUSIONS: This large multicenter study validates the Bacterial Meningitis Score prediction rule in the era of conjugate pneumococcal vaccine as an accurate decision support tool. The risk of bacterial meningitis is very low (0.1%) in patients with none of the criteria. The Bacterial Meningitis Score may be helpful to guide clinical decision making for the management of children presenting to emergency departments with CSF pleocytosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200475     DOI: 10.1001/jama.297.1.52

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  54 in total

Review 1.  Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.

Authors:  Matthijs C Brouwer; Allan R Tunkel; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

2.  CSF lactate for accurate diagnosis of community-acquired bacterial meningitis.

Authors:  S Giulieri; C Chapuis-Taillard; K Jaton; A Cometta; C Chuard; O Hugli; R Du Pasquier; J Bille; P Meylan; O Manuel; O Marchetti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-19       Impact factor: 3.267

3.  Eosinopenia as a marker of diagnosis and prognostic to distinguish bacterial from aseptic meningitis in pediatrics.

Authors:  Agathe Debray; Sylvie Nathanson; Florence Moulin; Jérome Salomon; Benjamin Davido
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-22       Impact factor: 3.267

4.  Management of acute meningitis.

Authors:  Michael J Griffiths; Fiona McGill; Tom Solomon
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

5.  Correction of Cerebrospinal Fluid Protein in Infants With Traumatic Lumbar Punctures.

Authors:  Todd W Lyons; Andrea T Cruz; Stephen B Freedman; Joseph L Arms; Paul L Aronson; Alesia H Fleming; Dina M Kulik; Prashant Mahajan; Rakesh D Mistry; Christopher M Pruitt; Amy D Thompson; Lise E Nigrovic
Journal:  Pediatr Infect Dis J       Date:  2017-10       Impact factor: 2.129

6.  Interpretation of Cerebrospinal Fluid White Blood Cell Counts in Young Infants With a Traumatic Lumbar Puncture.

Authors:  Todd W Lyons; Andrea T Cruz; Stephen B Freedman; Mark I Neuman; Fran Balamuth; Rakesh D Mistry; Prashant Mahajan; Paul L Aronson; Joanna E Thomson; Christopher M Pruitt; Samir S Shah; Lise E Nigrovic
Journal:  Ann Emerg Med       Date:  2016-12-29       Impact factor: 5.721

7.  Response.

Authors:  Michael J Griffiths; Fiona McGill; Tom Solomon
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

8.  Clinical Significance of Commensal Gram-Positive Rods Routinely Isolated from Patient Samples.

Authors:  Sixto M Leal; Melissa Jones; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2016-09-14       Impact factor: 5.948

9.  Risk score for identifying adults with CSF pleocytosis and negative CSF Gram stain at low risk for an urgent treatable cause.

Authors:  Rodrigo Hasbun; Merijn Bijlsma; Matthijs C Brouwer; Nabil Khoury; Christiane M Hadi; Arie van der Ende; Susan H Wootton; Lucrecia Salazar; Md Monir Hossain; Mark Beilke; Diederik van de Beek
Journal:  J Infect       Date:  2013-04-22       Impact factor: 6.072

10.  Diagnostic clinical and laboratory findings in response to predetermining bacterial pathogen: data from the Meningitis Registry.

Authors:  Maria Karanika; Vasiliki A Vasilopoulou; Antonios T Katsioulis; Panagiotis Papastergiou; Maria N Theodoridou; Christos S Hadjichristodoulou
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.